trial · primary record
Erdafitinib
Urothelial Cancer
| Phase | Phase 3 |
|---|---|
| Status | ACTIVE |
| Sponsor | Unknown |
| Enrolment | 629 |
| Primary completion | 2027-12-31 |
| Primary endpoint | Overall Survival (OS) |
| Registry ID | NCT03390504 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-04T03:54:14.253Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT03390504
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- Erdafitinib · approval
- Erdafitinib · compound